- Home
- COCP vs EDSA Comparison
COCP vs EDSA Comparison
Compare COCP & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- EDSA
- Stock Information
- Founded
- COCP 2006
- EDSA 2015
- Country
- COCP United States
- EDSA Canada
- Employees
- COCP N/A
- EDSA N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- EDSA Health Care
- Exchange
- COCP Nasdaq
- EDSA Nasdaq
- Market Cap
- COCP 15.5M
- EDSA 15.4M
- IPO Year
- COCP N/A
- EDSA N/A
- Fundamental
- Price
- COCP $1.46
- EDSA $2.45
- Analyst Decision
- COCP Strong Buy
- EDSA Strong Buy
- Analyst Count
- COCP 1
- EDSA 2
- Target Price
- COCP $6.00
- EDSA $13.00
- AVG Volume (30 Days)
- COCP 29.6K
- EDSA 20.7K
- Earning Date
- COCP 08-14-2025
- EDSA 08-08-2025
- Dividend Yield
- COCP N/A
- EDSA N/A
- EPS Growth
- COCP N/A
- EDSA N/A
- EPS
- COCP N/A
- EDSA N/A
- Revenue
- COCP N/A
- EDSA N/A
- Revenue This Year
- COCP N/A
- EDSA N/A
- Revenue Next Year
- COCP N/A
- EDSA N/A
- P/E Ratio
- COCP N/A
- EDSA N/A
- Revenue Growth
- COCP N/A
- EDSA N/A
- 52 Week Low
- COCP $1.12
- EDSA $1.55
- 52 Week High
- COCP $3.26
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- COCP 38.13
- EDSA 63.04
- Support Level
- COCP $1.37
- EDSA $2.26
- Resistance Level
- COCP $1.60
- EDSA $2.51
- Average True Range (ATR)
- COCP 0.09
- EDSA 0.12
- MACD
- COCP -0.01
- EDSA 0.01
- Stochastic Oscillator
- COCP 27.52
- EDSA 69.70
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.